When building a long-term share portfolio, I think it pays to start with ASX shares you would feel comfortable owning through good markets, bad markets, and everything in between.
That usually means blue chip ASX shares with strong competitive positions, recurring demand for their products or services, and management teams that have proven they can execute over time.
With that in mind, here are four ASX blue chip shares I would happily build a portfolio around.
Cochlear Ltd (ASX: COH)
The first blue chip ASX share that could be a buy is Cochlear. This hearing solutions company operates in a specialised medical niche supported by intellectual property, regulatory approvals, and decades of clinical data. Once a patient adopts Cochlear's technology, switching is rare, which helps create long-lasting revenue streams from upgrades and services.
The company's consistent investment in research and development is also a key part of its appeal. By prioritising innovation and long-term outcomes over short-term gains, Cochlear has built a business designed to remain relevant for decades.
REA Group Ltd (ASX: REA)
Another blue chip ASX share I would happily build a portfolio around is REA Group. Its property platforms sit at the centre of Australia's real estate ecosystem, benefiting from strong network effects that reinforce its market position. Buyers, sellers, and agents all rely on its services, which makes the business difficult to disrupt.
Importantly, REA is not dependent on rising property prices to grow. Product upgrades, premium services, and data-driven tools allow it to increase revenue per customer over time. This is supporting a sustainable and scalable business model.
ResMed Inc. (ASX: RMD)
A third blue chip ASX share that could be a buy is ResMed. It is a medical device company with demand drivers that extend well beyond economic cycles. The company operates in sleep apnoea and respiratory care, areas supported by ageing populations, rising diagnosis rates, and greater awareness of chronic health conditions.
Its devices, masks, and digital platforms are deeply entrenched in patient care, creating recurring revenue and strong customer relationships. And with a total addressable market estimated to be over 1 billion people, its long-term growth outlook is very positive.
TechnologyOne Ltd (ASX: TNE)
A final blue chip ASX share to consider is TechnologyOne. It is an enterprise software provider to governments, universities, and large organisations. Its move to a software-as-a-service model has transformed the business, improving revenue visibility and increasing recurring income.
TechnologyOne's products are deeply embedded within customer operations, making them difficult to replace. Combined with ongoing international expansion, this gives it a rare mix of defensiveness and growth within a blue chip structure.
